EU/3/16/1750

Table of contents

About

On 14 October 2016, orphan designation (EU/3/16/1750) was granted by the European Commission to Eiger Biopharmaceuticals Europe Ltd, United Kingdom, for exendin (9-39) for the treatment of noninsulinoma pancreatogenous hypoglycaemia syndrome.

The sponsorship was transferred to Eigerbio Europe Limited, Ireland, in August 2019.

Key facts

Active substance
Exendin (9-39)
Disease / condition
Treatment of noninsulinoma pancreatogenous hypoglycaemia syndrome
Date of first decision
14/10/2016
Outcome
Positive
EU designation number
EU/3/16/1750

Sponsor's contact details

Eigerbio Europe Limited
1 Castlewood Avenue
Rathmines
Dublin 6, D06 H685
Ireland
Tel. +1 650 272 6138
E-mail: info@eigerbio.com 

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

How useful was this page?

Add your rating